INCA035784 / Incyte - LARVOL DELTA

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Incyte Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Myeloproliferative Neoplasm • Oncology

INCA035784, A NOVEL, EQUIPOTENT T CELL–REDIRECTING ANTIBODY FOR PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS CARRYING DIFFERENT TYPES OF CALRETICULIN MUTATIONS (EHA 2025) - "INCA035784 does not bind to wtCALR when a stress agent such as doxorubicin induces its translocation to the cell surface...INCA035784 induced minimal levels of CRS-associated cytokines from HD PBMCs, HD T cells, and patient-derived PBMCs vs other T cell-engaging antibodies such as mosunetuzumab and vibecotamab, targeting CD20 and CD123, respectively... Overall, INCA035784 activates T cells in the presence of mutCALR complexed with TPOR on the cell surface. By binding to a unique, conserved epitope on the mutCALR N-domain, INCA035784 can target the diverse mutCALR variants found across the MPN patient population. INCA035784 also exhibits a low-risk profile with respect to cytokine induction."

Clinical • Myeloproliferative Neoplasm • Oncology • CALR • CD123 • CD34 • CD69 • IL2RA • IL3RA • MPL

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Incyte Corporation

New P1 trial • Myeloproliferative Neoplasm • Oncology